Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired disorders of platelet function.

Amy A Hassan1, Michael H Kroll

  • 1Thrombosis Research, Michael E DeBakey VA Medical Center, 2002 Holcombe Blvd., Houston, TX 77030, USA. mkroll@bcm.tmc.edu

Hematology. American Society of Hematology. Education Program
|November 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated natural language processing to identify venous thromboembolism from diagnostic imaging reports.

Blood vessels, thrombosis & hemostasis·2026
Same author

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Blood·2025
Same author

Mechanical Venous Thrombectomy for Deep Venous Thrombosis in Cancer Patients: A Single-Center Retrospective Study.

Cardiovascular and interventional radiology·2024
Same author

Checkpoint inhibitors.

Hematology. American Society of Hematology. Education Program·2023
Same author

Measurement of adherence and health-related quality of life during anticoagulation therapy in cancer-associated venous thromboembolism (VTE): a multicenter quantitative study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2023
Same author

Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism.

The oncologist·2023
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Platelet function disorders cause bleeding, often due to antiplatelet drugs or underlying conditions like uremia. Diagnosis involves bleeding time and platelet function tests, with treatments including addressing the cause and hemostatic drugs.

Area of Science:

  • Hematology
  • Internal Medicine

Background:

  • Qualitative platelet function abnormalities are crucial in mucocutaneous bleeding, especially when thrombocytopenia or von Willebrand disease are absent.
  • Acquired platelet disorders, frequently caused by antiplatelet drugs, present a significant clinical challenge.
  • Conditions such as uremia, hepatic cirrhosis, and myeloproliferative neoplasms are recognized contributors to platelet dysfunction.

Purpose of the Study:

  • To highlight the importance of considering qualitative platelet function abnormalities in bleeding patients.
  • To outline diagnostic approaches for suspected acquired platelet disorders.
  • To review available treatment strategies for diagnosed platelet dysfunction.

Main Methods:

  • Assessing bleeding time as a primary indicator.

Related Experiment Videos

  • Utilizing platelet function analyzers to measure platelet-dependent closure time.
  • Performing platelet aggregometry for detailed functional analysis.

    • Main Results:

    • Established diagnostic utility of bleeding time, closure time, and aggregometry in identifying platelet dysfunction.
    • Confirmed the link between various systemic diseases and acquired platelet disorders.
    • Demonstrated the availability of diverse therapeutic interventions.

    Conclusions:

    • Qualitative platelet dysfunction should be a key consideration in patients presenting with mucocutaneous bleeding.
    • A combination of clinical evaluation and specific laboratory tests aids in diagnosing acquired platelet disorders.
    • Management involves addressing the underlying etiology, supportive therapies like platelet transfusions, and targeted hemostatic agents.